Horizon Therapeutics plc HZNP announced that it has completed enrollment in the phase IV study evaluating its marketed drug, Tepezza (teprotumumab-trbw), for the treatment of thyroid eye disease (TED) ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する